这里是我们搜集到它的一些信息和数据，和前面那个药展示的数据是对照的，作

Here are some of the information and data we have collected. It is in contrast to the data shown by the previous drug. The mechanism of action, dose, safety, clinical trials, and effects are just two of this clinical trial. There is only one in front of it. One is for 2400 patients with systemic lupus erythematosus SLE in a three-stage double-blind randomization, and the other is a 104-week three-stage double-blind randomization for 448 patients with lupus kidney. The respective effects are listed in the bottom two. After you finish reading, there are still tables and histograms that visualize the key data.

Here is some of the information and data we collected it, and the previous drug show the data is controlled, the action of the machine, dose, safety, clinical trials, effects, but this clinical trial has two, there is only one, it is for the systemic lupus SLE 2400 three-stage double-blind random, and the other is for lupus kidney 448 104-week three-stage double-blind random, respectively, the efficacy of the bottom two columns. After you finish reading it, you still have a visualized table of key data, a bar chart.

Here is some information and data we have collected, which is compared with the data shown in the previous drug. The mechanism of action, dose, safety, clinical trials, and effects of the drug are only two. One is a double-blind randomized study of 2400 SLE patients with systemic lupus erythematosus (SLE) and 448 patients (104 weeks) with lupus nephritis Double blind randomization, the efficacy of each is listed in the bottom two. After you read it, there are still tables and bar charts to visualize the key data.<br>